Investigation of efficacy and safety of ticagrelor in elderly patients with acute coronary syndrome

被引:0
|
作者
Liu, Yang [1 ]
Liu, Heng-Liang [1 ]
Hao, Zhen-Xuan [1 ]
Chen, Qi [1 ]
Wang, Dan-Li [1 ]
Ji, Jin-Rui [1 ]
Liu, Jing [1 ]
Zhang, Sheng-Hao [1 ]
机构
[1] Southern Med Univ, Zhengzhou Peoples Hosp, Dept Cardiol, 33 Yellow River Rd, Zhengzhou 450000, Henan, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2019年 / 12卷 / 01期
关键词
Elderly; acute coronary syndrome; percutaneous coronary intervention; antiplatelet; hemorrhage; complications; ACUTE MYOCARDIAL-INFARCTION; RISK STRATIFICATION; ASIAN PATIENTS; CLOPIDOGREL; TIROFIBAN; OUTCOMES; INTERVENTION; ANTIPLATELET; INHIBITION; THERAPY;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: This study aims to investigate the efficacy and safety of dual antiplatelet therapy (DAPT) with ticagrelor and aspirin in elderly patients with Acute Coronary Syndrome (ACS). Methods: A total of 432 patients with ACS who underwent Percutaneous coronary intervention (PCI) were enrolled into the study. These patients were divided into three groups, according to age: non-elderly group (age: <60 years old, n=167), elderly group (age: 61-79 years old, n=209), and very elderly group (age: >= 80 years old, n=56). TIMI blood flow grade, TIMI myocardial perfusion grade (TMPG), major complications, 1-year follow-up bleeding events and the primary endpoint were observed and investigated after treatment with DAPT after PCI. Results: TIMI blood flow, TMPG, reinfarction during hospitalization, post-infarction angina pectoris, severe arrhythmia, incidence of cardiac function and cardiogenic shock (Killip III or above), incidence of total, severe and moderate bleeding events, and the primary and secondary endpoints at 1-year follow-up in the very elderly group were significantly higher, compared with the elderly group and non-elderly group. Conclusions: The probability of complications and hemorrhage was high in very elderly patients with ACS after DAPT with ticagrelor and aspirin following PCI.
引用
收藏
页码:1289 / 1298
页数:10
相关论文
共 50 条
  • [31] Comparison of ticagrelor and clopidogrel in anemic patients with acute coronary syndrome: efficacy and safety outcomes over one year
    Onuk, Tolga
    Polat, Fuat
    Yaylak, Baris
    Akyuz, Sukru
    Kolak, Zeynep
    Durak, Furkan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (05) : 759 - 770
  • [32] Comparison of ticagrelor and clopidogrel in anemic patients with acute coronary syndrome: efficacy and safety outcomes over one year
    Tolga Onuk
    Fuat Polat
    Barış Yaylak
    Şükrü Akyüz
    Zeynep Kolak
    Furkan Durak
    European Journal of Clinical Pharmacology, 2024, 80 : 759 - 770
  • [33] Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis
    Chen, Yundai
    Dong, Wei
    Wan, Zheng
    Li, Zhanquan
    Cong, Hongliang
    Hong, Tao
    Yin, Tong
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 201 : 545 - 546
  • [34] Efficacy and safety of prasugrel in acute coronary syndrome patients
    Nanau, Radu M.
    Delzor, Faustine
    Neuman, Manuela G.
    CLINICAL BIOCHEMISTRY, 2014, 47 (7-8) : 516 - 528
  • [35] Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome
    Laine, Marc
    Panagides, Vassili
    Frere, Corinne
    Cuisset, Thomas
    Gouarne, Caroline
    Jouve, Bernard
    Thuny, Franck
    Paganell, Franck
    Alessi, Marie-Christine
    Mancini, Julien
    Bonello, Aurent
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2019, 17 (12) : 2188 - 2195
  • [36] Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome Insights From the SWEDEHEART Registry
    Szummer, Karolina
    Montez-Rath, Maria E.
    Alfredsson, Joakim
    Erlinge, David
    Lindahl, Bertil
    Hofmann, Robin
    Ravn-Fischer, Annica
    Svensson, Per
    Jernberg, Tomas
    CIRCULATION, 2020, 142 (18) : 1700 - 1708
  • [37] Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes
    Lahu, Shqipdona
    Ndrepepa, Gjin
    Gewalt, Senta
    Schuepke, Stefanie
    Pellegrini, Costanza
    Bernlochner, Isabell
    Aytekin, Alp
    Neumann, Franz-Josef
    Menichelli, Maurizio
    Richardt, Gert
    Cassese, Salvatore
    Xhepa, Erion
    Kufner, Sebastian
    Sager, Hendrik B.
    Joner, Michael
    Ibrahim, Tareq
    Fusaro, Massimiliano
    Laugwitz, Karl-Ludwig
    Schunkert, Heribert
    Kastrati, Adnan
    Mayer, Katharina
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 338 : 8 - 13
  • [38] Efficacy and Safety of Ticagrelor Monotherapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Retrospective Study
    Song, Dan
    Chen, Ziwen
    HEART SURGERY FORUM, 2024, 27 (10) : E1150 - E1156
  • [39] Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
    Yildirim, Mustafa
    Mueller-Hennessen, Matthias
    Milles, Barbara Ruth
    Biener, Moritz
    Hund, Hauke
    Frey, Norbert
    Giannitsis, Evangelos
    Salbach, Christian
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (16):
  • [40] Efficacy and safety of rivaroxaban and ticagrelor in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention
    Liu, Xinbing
    Wang, Linlin
    Zhou, Mingcheng
    Feng, Liuliu
    CONTEMPORARY CLINICAL TRIALS, 2021, 104